Exane Derivatives’s Corbus Pharmaceuticals CRBP Stock Holding History

Exane Derivatives’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$668	Sell	88 -71	-45%	-$686	﹤0.01%	543
2022 Q1	$2.53K	Hold	159	–	–	﹤0.01%	738
2021 Q4	$2.93K	Hold	159	–	–	﹤0.01%	644
2021 Q3	$4.86K	Hold	159	–	–	﹤0.01%	741
2021 Q2	$7.58K	Hold	159	–	–	﹤0.01%	754
2021 Q1	$9.39K	Hold	159	–	–	﹤0.01%	598
2020 Q4	$5.96K	Hold	159	–	–	﹤0.01%	549
2020 Q3	$8.58K	Hold	159	–	–	﹤0.01%	471
2020 Q2	$40K	Hold	159	–	–	0.01%	370
2020 Q1	$25K	Hold	159	–	–	0.01%	399
2019 Q4	$33.1K	Sell	159 -865	-84%	-$128K	0.01%	374
2019 Q3	$150K	Sell	1,024 -159	-13%	-$27.7K	0.03%	279
2019 Q2	$246K	Buy	+1,183	New	+$253K	0.04%	240

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Exane Derivatives's CRBP Position: Q2 2022 in Review

Exane Derivatives reduced its Corbus Pharmaceuticals (CRBP) stake by 45% in Q2 2022, selling an estimated $686 and leaving 88 shares worth $668. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Exane Derivatives first reported a position in CRBP in Q2 2019 and has held it in 13 quarters since. The position peaked at $246K in Q2 2019. 70 funds tracked by Wall St. Rank hold CRBP as of Q2 2022.

Exane Derivatives held 88 shares of Corbus Pharmaceuticals worth $668 as of Q2 2022.
Exane Derivatives sold 71 Corbus Pharmaceuticals shares in Q2 2022, an estimated $686.
Corbus Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #543 holding.
Exane Derivatives first reported a position in Corbus Pharmaceuticals in Q2 2019 and has held it in 13 quarters since.
Exane Derivatives's Corbus Pharmaceuticals position peaked at $246K in Q2 2019.
70 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.